AngioDynamicsANGO
ANGO
About: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Employees: 748
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
133% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 15
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
14% more funds holding
Funds holding: 134 [Q4 2024] → 153 (+19) [Q1 2025]
9% more capital invested
Capital invested by funds: $303M [Q4 2024] → $330M (+$27.3M) [Q1 2025]
5.37% more ownership
Funds ownership: 81.41% [Q4 2024] → 86.79% (+5.37%) [Q1 2025]
22% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 58
31% less call options, than puts
Call options by funds: $351K | Put options by funds: $510K
Research analyst outlook
We haven’t received any recent analyst ratings for ANGO.
Financial journalist opinion
Neutral
Business Wire
4 days ago
AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2025 before the market open on Tuesday, July 15, 2025. The Company's management will host a conference call at 8:00 am ET the same day to.
Neutral
Business Wire
2 weeks ago
AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life, today announced the first patient has been enrolled in the RECOVER-AV clinical trial, a prospective, multi-center, multi-national, single-arm study evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in t.
Negative
Zacks Investment Research
1 month ago
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
Positive
Zacks Investment Research
1 month ago
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
Positive
Zacks Investment Research
1 month ago
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Negative
Zacks Investment Research
1 month ago
Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?
Here is how AngioDynamics (ANGO) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
3 months ago
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
3 months ago
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
3 months ago
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.
Charts implemented using Lightweight Charts™